Sclerostin is also positively associated with pulse wave velocity for arterial stiffness in postmenopausal women, nondialyzed CKD patients, HD patients, and kidney transplant recipients and thus could be a biomarker for the cardiovascular changes in the CKD–MBD spectrum [22, 25, 36, 37]. This evidence concerns the gene SOST and chronic kidney disease.